Wolff, Daniel and Schleuning, Michael and von Harsdorf, Stephanie and Bacher, Ulrike and Gerbitz, Armin and Stadler, Michael and Ayuk, Francis and Kiani, Alexander and Schwerdtfeger, Rainer and Vogelsang, Georgia B. and Kobbe, Guido and Gramatzki, Martin and Lawitschka, Anita and Mohty, Mohamad and Pavletic, Steven Z. and Greinix, Hildegard and Holler, Ernst (2011) Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17 (1). pp. 1-17. ISSN 1083-8791, 1523-6536
Full text not available from this repository. (Request a copy)Abstract
Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant morbidity and mortality. Although first-line treatment of cGVHD is based on controlled trials, second-line treatment is almost solely based on phase II trials or retrospective analyses. The consensus conference on clinical practice in cGVHD held in Regensburg aimed to achieve a consensus on the current evidence of treatment options as well as to provide guidelines for daily clinical practice. Treatment modalities are the use of steroids and calcineurin inhibitors as well as immunomodulating modalities (photopheresis, mTOR-inhibitors, thalidomide, hydroxychloroquine, vitamin A analogs, clofazimine), and cytostatic agents (mycophenolate mofetil, methotrexate, cyclophosphamide, pentostatin). Recent reports showed some efficacy of rituximab, alemtuzumab, and etanercept in selected patients. Moreover, tyrosine kinase inhibitors such as imatinib came into the field because of their ability to interfere with the platelet-derived growth factor (PDGF-R) pathway involved in fibrosis. An other treatment option is low-dose thoracoabdominal irradiation. Although different treatment options are available, the "trial-and-error system" remains the only way to identify the drug effective in the individual patient, and valid biomarkers are eagerly needed to identify the likelihood of response to a drug in advance. Moreover, the sparse evidence for most treatment entities indicates the urgent need for systematic evaluation of second-line treatment options in cGVHD. Biol Blood Marrow Transplant 17: 1-17 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEM-CELL TRANSPLANTATION; WORKING GROUP-REPORT; STEROID-REFRACTORY ACUTE; BONE-MARROW-TRANSPLANTATION; LOW-DOSE METHOTREXATE; MONOCLONAL-ANTIBODY TREATMENT; RECEPTOR FUSION PROTEIN; RESISTANT CHRONIC GVHD; REGULATORY T-CELLS; MYCOPHENOLATE-MOFETIL; Allogeneic hematopoietic stem cell transplantation; Chronic GVHD; Bone marrow transplantation; Immunosuppressive therapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Jun 2020 08:28 |
| Last Modified: | 29 Jun 2020 08:28 |
| URI: | https://pred.uni-regensburg.de/id/eprint/21495 |
Actions (login required)
 |
View Item |
